Anti-Orai1 antibody
First Claim
Patent Images
1. An antibody or an antigen binding fragment of the antibody which specifically binds to the amino acid sequence represented by SEQ ID NO:
- 2, wherein the heavy chain sequence comprises a variable region having CDRH1, CDRH2, and CDRH3, andthe light chain sequence comprises a variable region having CDRL1, CDRL2, and CDRL3 wherein the antibody or antigen binding fragment of the antibody is characterized by one of the following;
(a) wherein the CDRH1 consists of the amino acid sequence represented by SEQ ID NO;
102, the CDRH2 consists of the amino acid sequence represented by SEQ ID NO;
106, the CDRH3 consists of the amino acid sequence represented by SEQ ID NO;
110, the CDRL1 consists of the amino acid sequence represented by SEQ ID NO;
94, the CDRL2 consists of the amino acid sequence represented by SEQ ID NO;
97, and the CDRL3 consists of the amino acid sequence represented by SEQ ID NO;
101;
(b) wherein the CDRH1 consists of the amino acid sequence represented by SEQ ID NO;
102, the CDRH2 consists of the amino acid sequence represented by SEQ ID NO;
106, the CDRH3 consists of the amino acid sequence represented by SEQ ID NO;
110, the CDRL1 consists of the amino acid sequence represented by SEQ ID NO;
95, the CDRL2 consists of the amino acid sequence represented by SEQ ID NO;
98, and the CDRL3 consists of the amino acid sequence represented by SEQ ID NO;
101;
(c) wherein the CDRH1 consists of the amino acid sequence represented by SEQ ID NO;
102, the CDRH2 consists of the amino acid sequence represented by SEQ ID NO;
107, the CDRH3 consists of the amino acid sequence represented by SEQ ID NO;
110, the CDRL1 consists of the amino acid sequence represented by SEQ ID NO;
93, the CDRL2 consists of the amino acid sequence represented by SEQ ID NO;
96, and the CDRL3 consists of the amino acid sequence represented by SEQ ID NO;
101;
(d) wherein the CDRH1 consists of the amino acid sequence represented by SEQ ID NO;
102, the CDRH2 consists of the amino acid sequence represented by SEQ ID NO;
108, the CDRH3 consists of the amino acid sequence represented by SEQ ID NO;
110, the CDRL1 consists of the amino acid sequence represented by SEQ ID NO;
93, the CDRL2 consists of the amino acid sequence represented by SEQ ID NO;
96, and the CDRL3 consists of the amino acid sequence represented by SEQ ID NO;
101; and
(e) wherein the CDRH1 consists of the amino acid sequence represented by SEQ ID NO;
102, the CDRH2 consists of the amino acid sequence represented by SEQ ID NO;
104, the CDRH3 consists of the amino acid sequence represented by SEQ ID NO;
109, the CDRL1 consists of the amino acid sequence represented by SEQ ID NO;
93, the CDRL2 consists of the amino acid sequence represented by SEQ ID NO;
96, and the CDRL3 consists of the amino acid sequence represented by SEQ ID NO;
101.
0 Assignments
0 Petitions
Accused Products
Abstract
It is intended to provide a therapeutic and/or prophylactic agent for transplant rejections, immunological diseases, allergic diseases, inflammatory diseases, thrombosis, cancers, etc., targeting human Orai1. The present invention provides, for example, a pharmaceutical composition comprising an antibody that specifically recognizes human Orai1 and has the activity of inhibiting human T cell activation.
-
Citations
19 Claims
-
1. An antibody or an antigen binding fragment of the antibody which specifically binds to the amino acid sequence represented by SEQ ID NO:
- 2, wherein the heavy chain sequence comprises a variable region having CDRH1, CDRH2, and CDRH3, and
the light chain sequence comprises a variable region having CDRL1, CDRL2, and CDRL3 wherein the antibody or antigen binding fragment of the antibody is characterized by one of the following; (a) wherein the CDRH1 consists of the amino acid sequence represented by SEQ ID NO;
102, the CDRH2 consists of the amino acid sequence represented by SEQ ID NO;
106, the CDRH3 consists of the amino acid sequence represented by SEQ ID NO;
110, the CDRL1 consists of the amino acid sequence represented by SEQ ID NO;
94, the CDRL2 consists of the amino acid sequence represented by SEQ ID NO;
97, and the CDRL3 consists of the amino acid sequence represented by SEQ ID NO;
101;(b) wherein the CDRH1 consists of the amino acid sequence represented by SEQ ID NO;
102, the CDRH2 consists of the amino acid sequence represented by SEQ ID NO;
106, the CDRH3 consists of the amino acid sequence represented by SEQ ID NO;
110, the CDRL1 consists of the amino acid sequence represented by SEQ ID NO;
95, the CDRL2 consists of the amino acid sequence represented by SEQ ID NO;
98, and the CDRL3 consists of the amino acid sequence represented by SEQ ID NO;
101;(c) wherein the CDRH1 consists of the amino acid sequence represented by SEQ ID NO;
102, the CDRH2 consists of the amino acid sequence represented by SEQ ID NO;
107, the CDRH3 consists of the amino acid sequence represented by SEQ ID NO;
110, the CDRL1 consists of the amino acid sequence represented by SEQ ID NO;
93, the CDRL2 consists of the amino acid sequence represented by SEQ ID NO;
96, and the CDRL3 consists of the amino acid sequence represented by SEQ ID NO;
101;(d) wherein the CDRH1 consists of the amino acid sequence represented by SEQ ID NO;
102, the CDRH2 consists of the amino acid sequence represented by SEQ ID NO;
108, the CDRH3 consists of the amino acid sequence represented by SEQ ID NO;
110, the CDRL1 consists of the amino acid sequence represented by SEQ ID NO;
93, the CDRL2 consists of the amino acid sequence represented by SEQ ID NO;
96, and the CDRL3 consists of the amino acid sequence represented by SEQ ID NO;
101; and(e) wherein the CDRH1 consists of the amino acid sequence represented by SEQ ID NO;
102, the CDRH2 consists of the amino acid sequence represented by SEQ ID NO;
104, the CDRH3 consists of the amino acid sequence represented by SEQ ID NO;
109, the CDRL1 consists of the amino acid sequence represented by SEQ ID NO;
93, the CDRL2 consists of the amino acid sequence represented by SEQ ID NO;
96, and the CDRL3 consists of the amino acid sequence represented by SEQ ID NO;
101. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)
- 2, wherein the heavy chain sequence comprises a variable region having CDRH1, CDRH2, and CDRH3, and
Specification